Ori Biotech, a leader in cell and gene therapy (CGT) manufacturing technologies, and the Cell Therapy Manufacturing Center (CTMC), a joint venture between National Resilience Inc. and MD Anderson Cancer Center, have entered a collaborative partnership to develop industrial manufacturing processes for cell therapies.
The partnership will accelerate process development, clinical implementation, and commercialization of novel cell therapies. Furthermore, it will combine Ori’s technology platform with CTMC’s manufacturing capabilities and, in the first instance, will focus on a cell therapy invented by Dr. Sattva Neelapu, professor of Lymphoma/Myeloma at MD Anderson. The partnership enables CTMC pre-commercial access to Ori’s technology as part of its LightSpeed Early Access Program (LEAP).
